Show simple item record

dc.contributor.authorVyse, S
dc.contributor.authorThway, K
dc.contributor.authorHuang, PH
dc.contributor.authorJones, RL
dc.date.accessioned2021-05-18T15:45:44Z
dc.date.available2021-05-18T15:45:44Z
dc.date.issued2021-04-28
dc.identifier.citationCurrent opinion in oncology, 2021
dc.identifier.issn1040-8746
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4558
dc.identifier.eissn1531-703X
dc.identifier.eissn1531-703X
dc.identifier.eissn1531-703X
dc.identifier.eissn1531-703Xen_US
dc.identifier.doi10.1097/cco.0000000000000741
dc.identifier.doi10.1097/cco.0000000000000741
dc.identifier.doi10.1097/cco.0000000000000741
dc.identifier.doi10.1097/cco.0000000000000741en_US
dc.description.abstractPurpose of review Next-generation sequencing (NGS) has enabled fast, high-throughput nucleotide sequencing and has begun to be implemented into clinical practice for genomic-guided precision medicine in various cancer types. This review will discuss recent evidence that highlights opportunities for NGS to improve outcomes in sarcomas that have complex genomic profiles with no known driver mutations.Recent findings Global genomic signatures detectable by NGS including tumour mutational burden and microsatellite instability have potential as biomarkers for response to immunotherapy in certain sarcoma subtypes including angiosarcomas. Identification of hallmarks associated with 'BRCAness' and homologous recombination repair defects in leiomyosarcomas and osteosarcomas may predict sensitivity to poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors. Lastly, the use of NGS for evaluating cancer predisposition in sarcomas may be useful for early detection, screening and surveillance.Summary Currently, the implementation of NGS for every sarcoma patient is not practical or useful. However, adopting NGS as a complementary approach in sarcomas with complex genomics and those with limited treatment options has the potential to deliver precision medicine to a subgroup of patients, with novel therapies such as immune checkpoint and PARP inhibitors. Moving forward, molecular tumour boards incorporating multidisciplinary teams of pathologists, oncologists and genomic specialists to interpret NGS data will complement existing tools in diagnosis and treatment decision making in sarcoma patients.
dc.formatPrint-Electronic
dc.languageeng
dc.language.isoeng
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleNext-generation sequencing for the management of sarcomas with no known driver mutations.
dc.typeJournal Article
dcterms.dateAccepted2021-04-28
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1097/cco.0000000000000741
rioxxterms.licenseref.startdate2021-04-28
rioxxterms.licenseref.startdate2021-04-28en_US
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCurrent opinion in oncology
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology
pubs.publication-statusPublished
pubs.embargo.termsNo embargo
icr.researchteamMolecular and Systems Oncology
icr.researchteamMolecular and Systems Oncologyen_US
dc.contributor.icrauthorHuang, Paulen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/